SEC Form 4 · accession 0000899243-16-012641
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric D. Shaff
Officer — CFO and EVP
Period of report
Feb 1, 2016
Accepted (ET)
Feb 3, 2016 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $26.20 | Feb 1, 2016 | A | 78,500 | A | — | Jan 31, 2026 | Common Stock | 78,500 | 78,500 | D |
Explanation of responses
- F1The option vests as to 25% of the shares subject to the option on February 1, 2017, and as to an additional 6.25% of the total number of shares subject to the option upon the completion of each three consecutive months of service thereafter.